Produktname:Methyl 4-amino-2,3-difluoro-5-nitrobenzoate
IUPAC Name:methyl 4-amino-2,3-difluoro-5-nitrobenzoate
- CAS：284030-58-6
- Molekulare Formel：C8H6F2N2O4
- Reinheit：95%+
- Katalognummer：CM157680
- Molekulargewicht：232.14
Nur für den Einsatz in Forschung und Entwicklung..
Produkt-Details
- CAS-Nr.:284030-58-6
- Molekulare Formel:C8H6F2N2O4
- Schmelzpunkt:-
- SMILES-Code:O=C(OC)C1=CC([N+]([O-])=O)=C(N)C(F)=C1F
- Dichte:
- Katalognummer:CM157680
- Molekulargewicht:232.14
- Siedepunkt:402°C at 760 mmHg
- Mdl-Nr.:
- Lagerung:Keep in a tight container and store at ambient temperature，protect from light
Category Infos
- Benzenes
- Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.
Column Infos
- Encorafenib plus Binimetinib
- U.S. FDA approved Pfizer's BRAFTOVI® (Encorafenib) + MEKTOVI® (Binimetinib) for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation. The FDA's approval is based on data from the ongoing Phase 2 PHAROS clinical trial. Encorafenib is an oral small molecule BRAF kinase inhibitor, and Binimetinib is an oral small molecule MEK inhibitor targeting key proteins in the MAPK signaling pathway (RAS-RAF-MEK-ERK).
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.
Suche 
+86 21 5895 0110 
